{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:37:07Z","timestamp":1790235427690,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1124\/dmd.121.000484","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T21:55:50Z","timestamp":1622152550000},"page":"610-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes"],"prefix":"10.1016","volume":"49","author":[{"given":"Eman","family":"El-Khateeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubida M.","family":"Al-Majdoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahim","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000484_bib1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/dmd.116.074732","article-title":"Global proteomic analysis of human liver microsomes: rapid characterization and quantification of hepatic drug-metabolizing enzymes","volume":"45","author":"Achour","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cpt.2102","article-title":"Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters","volume":"109","author":"Achour","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/dmd.117.079475","volume":"46","author":"Achour","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1208\/s12248-014-9712-6","article-title":"Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis","volume":"17","author":"Al Feteisi","year":"2015","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000484_bib5","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1002\/1873-3468.13982","article-title":"Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin","volume":"594","author":"Al-Majdoub","year":"2020","journal-title":"FEBS Lett"},{"key":"10.1124\/dmd.121.000484_bib6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1021\/acs.molpharmaceut.8b01189","article-title":"Proteomic quantification of human blood\u2013brain barrier SLC and ABC transporters in healthy individuals and dementia patients","volume":"16","author":"Al-Majdoub","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.121.000484_bib7","doi-asserted-by":"crossref","unstructured":"Al-Majdoub ZM, Couto N, Achour B, Harwood MD, Carlson G, Warhurst G, Barber J, Rostami-Hodjegan A. (2020b). Quantification of proteins involved in intestinal epithelial handling of enobiotics. Clin. Pharmacol. Ther., cpt.2097.","DOI":"10.1002\/cpt.2097"},{"key":"10.1124\/dmd.121.000484_bib8","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1021\/acsomega.9b02002","article-title":"Peptide selection for accurate targeted protein quantification via a dimethylation high-resolution mass spectrum strategy with a peptide release kinetic model","volume":"5","author":"Chen","year":"2020","journal-title":"ACS Omega"},{"key":"10.1124\/dmd.121.000484_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ab.2018.03.019","article-title":"Quantification of proteins by data independent acquisition: performance assessment of the Hi3 methodology","volume":"549","author":"Chevreux","year":"2018","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.121.000484_bib10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/acs.molpharmaceut.8b00941","article-title":"Quantification of proteins involved in drug metabolism and disposition in the human liver using label-free global proteomics","volume":"16","author":"Couto","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.121.000484_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.1301","article-title":"Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens","volume":"105","author":"Drozdzik","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000484_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1389200043489054","article-title":"The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes","volume":"5","author":"Elbekai","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000484_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/dmd.120.000152","article-title":"Scaling factors for clearance in adult liver cirrhosis","volume":"48","author":"El-Khateeb","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib15","doi-asserted-by":"crossref","unstructured":"El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A (2021) Time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther (In Production). https:\/\/doi.org\/10.1111\/apt.16489.","DOI":"10.1111\/apt.16489"},{"key":"10.1124\/dmd.121.000484_bib16","doi-asserted-by":"crossref","first-page":"107397","DOI":"10.1016\/j.pharmthera.2019.107397","article-title":"Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: applications in translational pharmacology and recommendations for best practice","volume":"203","author":"El-Khateeb","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcph.1702","article-title":"Discordance between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: implications on dosing recommendations for oncology compounds","volume":"61","author":"Elmeliegy","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000484_bib18","unstructured":"EMA (2005). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Ema, 1-10 CPMP\/EWP\/2339\/02. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf"},{"key":"10.1124\/dmd.121.000484_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euprot.2014.06.001","article-title":"Comparison of label-free quantification methods for the determination of protein complexes subunits stoichiometry","volume":"4","author":"Fabre","year":"2014","journal-title":"EuPA Open Proteom"},{"key":"10.1124\/dmd.121.000484_bib20","unstructured":"FDA (2003). Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. FDA Guid. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and"},{"key":"10.1124\/dmd.121.000484_bib21","unstructured":"FDA (2020). Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs guidance for industry. Guid. Doc. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial"},{"key":"10.1124\/dmd.121.000484_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450--mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/dmd.115.067777","article-title":"In vitro-in vivo extrapolation scaling factors for intestinal P-glycoprotein and breast cancer resistance protein: part II. The impact of cross-laboratory variations of intestinal transporter relative expression factors on predicted drug disposition","volume":"44","author":"Harwood","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","article-title":"Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance","volume":"2","author":"Jamei","year":"2016","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/dmd.121.000484_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000484_bib26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/pr401017h","article-title":"Accurate label-free protein quantitation with high- and low-resolution mass spectrometers","volume":"13","author":"Krey","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1124\/dmd.121.000484_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/pr200748h","article-title":"Systematic comparison of label-free, metabolic labeling, and isobaric chemical labeling for quantitative proteomics on LTQ Orbitrap Velos","volume":"11","author":"Li","year":"2012","journal-title":"J Proteome Res"},{"key":"10.1124\/dmd.121.000484_bib28","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.121.000484_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbapap.2013.07.017","article-title":"Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines","volume":"1844","author":"Megger","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.121.000484_bib30","first-page":"19","article-title":"Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry","volume":"30","author":"Pitt","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"10.1124\/dmd.121.000484_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt.1537","article-title":"Toward a consensus on applying quantitative liquid chromatography-tandem mass spectrometry proteomics in translational pharmacology research: a white paper","volume":"106","author":"Prasad","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","article-title":"Abundance of phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study","volume":"46","author":"Prasad","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib33","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1208\/s12248-014-9602-y","article-title":"Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics","volume":"16","author":"Prasad","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000484_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpt.904","article-title":"Reverse translation in PBPK and QSP: going backwards in order to go forward with confidence","volume":"103","author":"Rostami-Hodjegan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000484_bib35","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1021\/pr400279u","article-title":"Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters","volume":"12","author":"Russell","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1124\/dmd.121.000484_bib36","doi-asserted-by":"crossref","first-page":"e2000093","DOI":"10.1002\/pmic.202000093","article-title":"Benchmarking accuracy and precision of intensity-based absolute quantification of protein abundances in Saccharomyces cerevisiae","volume":"21","author":"S\u00e1nchez","year":"2021","journal-title":"Proteomics"},{"key":"10.1124\/dmd.121.000484_bib37","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000484_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"Schwanh\u00e4usser","year":"2011","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1124\/dmd.121.000484_bib39","first-page":"S17","article-title":"Utility of quantitative proteomics for enhancing the predictive ability of physiologically based pharmacokinetic models across disease states","volume":"60","author":"Sharma","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000484_bib40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000484_bib41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/dmd.117.079285","article-title":"Comparison of proteomic quantification approaches for hepatic drug transporters: multiplexed global quantitation correlates with targeted proteomic quantitation","volume":"46","author":"Vildhede","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000484_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2020.1702022","article-title":"Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations","volume":"16","author":"Weersink","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000484_bib43","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1021\/acs.molpharmaceut.7b00364","article-title":"Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes","volume":"14","author":"Wegler","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.121.000484_bib44","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1074\/mcp.M113.037309","article-title":"A \u201cproteomic ruler\u201d for protein copy number and concentration estimation without spike-in standards","volume":"13","author":"Wi\u015bniewski","year":"2014","journal-title":"Mol Cell Proteomics"},{"key":"10.1124\/dmd.121.000484_bib45","first-page":"217","article-title":"Multiple-enzyme-digestion strategy improves accuracy and sensitivity of label- and standard-free absolute quantification to a level that is achievable by analysis with stable isotope-labeled standard spiking","volume":"18","author":"Wi\u015bniewski","year":"2019","journal-title":"J Proteome Res"},{"key":"10.1124\/dmd.121.000484_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wi\u015bniewski","year":"2009","journal-title":"Nat Methods"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:18:24Z","timestamp":1739956704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624077055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0090955624077055"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000484","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomic Quantification of Changes in Abundance of Drug-Metabolizing Enzymes and Drug Transporters in Human Liver Cirrhosis: Different Methods, Similar Outcomes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}